Comparative Pharmacology
Head-to-head clinical analysis: ASENDIN versus VIVACTIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASENDIN versus VIVACTIL.
ASENDIN vs VIVACTIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amoxapine, a dibenzoxazepine tricyclic antidepressant, primarily inhibits the reuptake of norepinephrine and serotonin. Its metabolite, 7-hydroxyamoxapine, exhibits dopamine D2 receptor antagonism, contributing to its antipsychotic effects.
Norepinephrine and serotonin reuptake inhibitor; also has anticholinergic and antihistaminergic activity.
50 mg orally three times daily, increased gradually to 100-200 mg/day in divided doses. Max 300 mg/day.
10 mg orally twice daily (morning and afternoon) or 10 mg once daily at bedtime; may increase gradually to 60 mg/day in divided doses.
None Documented
None Documented
Terminal elimination half-life is approximately 24-30 hours. Clinical context: Steady-state is reached within 5-7 days; the half-life supports once-daily dosing in most patients.
Terminal elimination half-life ranges 18–34 hours (mean ~25 hours); clinical steady-state achieved within 5–7 days.
Renal (approximately 50% as unchanged drug and metabolites), biliary/fecal (30-40%), with the remainder as other metabolites; <10% excreted unchanged in urine.
Primarily renal (approximately 70% as metabolites, <5% unchanged), with the remainder via fecal/biliary elimination.
Category C
Category C
Tricyclic Antidepressant
Tricyclic Antidepressant